El interés en corto de Cardiol Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Cardiol Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Cardiol Therapeutics (NASDAQ:CRDL) Bolsa, Informe de interés en corto

Cardiol Therapeutics

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics Inc

The U.S. private sector activity posted its fastest pace of expansion in more than two and a half years in November, driven by exceptional growth in the services sector, which continues to far exceed even the most <a href="https://www.benzinga.com/news/econ-s">optimistic forecasts by economists.</a>
Business sentiment indicators in both the services and manufacturing sectors, as measured by S&amp;P Global&#8217;s Purchasing Managers&#8217; Index (PMI), improved in November. The services sector recorded its strongest growth since March 2022, while manufacturing saw a slower pace of contraction.
<h3 class="wp-block-heading">US November S&amp;P Global&#8217;s PMI Report: Key Highlights</h3>
<ul>
<li>The Flash Composite PMI rose from 54.1 in October to 55.3 in November, marking the strongest growth since April 2022. </li>
<li>The Flash Services PMI also soared from 55 to 57, surpassing estimates of 57.2 as tracked by TradingEconomics. </li>
<li>The Flash Manufacturing PMI inched up from 48.5 to 48.8, matching expectations. </li>
<li>Companies&#8217; outlook for the year ahead rose to their highest levels since May 2022, fueled by optimism over potential interest rate cuts, stronger economic growth, and more favorable business policies anticipated by the new administration in 2025.</li>
<li>Employment declined for the fourth consecutive month, while output price inflation eased to its lowest level since June 2020.</li>
<li>While growth remained concentrated in the services sector, increased optimism and renewed hiring in manufacturing signaled the potential for a broader recovery in the months ahead.</li>
</ul>
&#8220;The rise in the headline flash PMI indicates that economic growth is accelerating in the fourth quarter, while at the same time inflationary pressures are cooling,&#8221; said Chris Williamson, chief business economist at S&amp;P Global Market Intelligence.
According to Williamson, the survey&#8217;s price index for goods and services suggests that consumer inflation is running significantly below the Federal Reserve&#8217;s 2% target.
Williamson also highlighted the increasing optimism for next-year output from goods-producing businesses. &#8220;The promise of greater protectionism and tariffs has helped lift confidence in the U.S. good producing sector, which is already feeding through to higher factory employment,&#8221; he said.
<h3 class="wp-block-heading">Market reactions: Stocks rise, dollar holds at 2-year highs</h3>
A new round of strong economic data fueled a rally in U.S. stocks, particularly among those most sensitive to domestic economic momentum.
Small-cap stocks, tracked by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), rallied 1.2% on Friday, aiming for their fifth consecutive session of gains.
Blue-chip stocks also posted solid performances, with the Dow Jones, represented by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), climbing 0.5% and surpassing the 44,000 mark.
The U.S. dollar index (DXY), tracked via the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), held steady with a 0.6% gain after touching fresh two-year highs<a href="https://www.benzinga.com/news/econ-s/24/11/42138717/dollar-hits-2-year-highs-as-europes-recession-signals-spark-euro-pound-sell-offs"> earlier in the session.</a>
Meanwhile, Treasury yields remained flat, and gold advanced 1.1%, also targeting its fifth straight session of gains.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42137929/2025-us-economy-outlook-cloudier-than-normal-jpmorgan-says-boom-bust-scenarios">2025 US Economy Outlook &#8216;Cloudier Than Normal,&#8217; JPMorgan Says: Boom, Bust Scenarios</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

ETFs

SPDR Dow Jones Industrial Average ETF Trust

PowerShares DB US Dollar Index Bullish Fund

US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000

Piper Sandler analyst Kashy Harrison maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Overweight and raises the price target from $20 to $30.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Bloom Energy, Raises Price Target to $30

Piper Sandler analyst Adam Butler assumes TFS Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFSL#NASDAQ">TFSL</a>) with a Neutral rating and announces Price Target of $15.

Initiation

TFSL

Piper Sandler Assumes TFS Financial at Neutral, Announces Price Target of $15

Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares are trading lower by 10% to $25.13 in November and are near <a href="https://www.benzinga.com/general/biotech/24/11/42015727/stock-of-the-day-is-pfizer-set-up-to-rally">decade-lows</a> after President-elect Donald Trump last week <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">announced his intention</a> to nominate Robert F. Kennedy Jr. to lead the Department of Health and Human Services (HHS).
The decision has heightened concerns over potential policy shifts in vaccine regulation and pharmaceutical oversight, areas central to Pfizer's business.
What To Know: Kennedy, a known vaccine skeptic, has previously promoted discredited theories <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill">linking vaccines to autism</a>. His appointment raises questions about the direction of U.S. health policy under Trump's administration, particularly regarding vaccine guidelines and FDA regulatory practices. 
Pfizer, a global leader in vaccine development with products like the Prevnar pneumonia vaccine and its groundbreaking COVID-19 vaccine, could face new challenges if Kennedy's policies alter vaccine recommendations or erode public trust.
Read Also: <a href="https://www.benzinga.com/24/11/42119511/eli-lilly-stock-tumbles-as-rfk-jr-targets-weight-loss-drugs-buying-opportunity">Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs</a>
In addition to vaccines, Pfizer's broader pharmaceutical operations, including its oncology, rare disease and cardiovascular drug segments, may also be affected by changes in FDA approval processes or drug pricing strategies under Kennedy's tenure. His criticism of pharmaceutical companies' influence over public health has fueled speculation about potential reforms targeting industry practices.
Analysts warn that any major shifts in <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">vaccine policy</a> or regulatory frameworks could have far-reaching consequences for the pharmaceutical sector, with Pfizer among the most exposed.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous">Robert Kennedy Jr. Poised To Lead Health And Human Services: Why FDA, NIH Officials Are Nervous</a>
<h2 class="wp-block-heading">How To Buy PFE Stock</h2>
By now you're likely curious about how to participate in the market for Pfizer &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PFE has a 52-week high of $31.54 and a 52-week low of $24.48.

Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination

Piper Sandler analyst Kashy Harrison downgrades Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Overweight to Neutral and lowers the price target from $23 to $11.

Downgrades

Piper Sandler Downgrades Sunrun to Neutral, Lowers Price Target to $11

<a href="https://www.hollywoodreporter.com/movies/movie-features/wicked-box-office-gladiator-previews-1236069327/">https://www.hollywoodreporter.com/movies/movie-features/wicked-box-office-gladiator-previews-1236069327/</a>
Call it whatever you want &mdash; Glicked, Wikiator or Barbienheimer 2.0. The only thing that matters is that the domestic <a href="https://www.hollywoodreporter.com/t/box-office/">box office</a> is <a href="https://www.hollywoodreporter.com/movies/movie-news/moana-2-tracking-record-thanksgiving-opening-1236055787/">springing back to life in historic fashio</a>n thanks to the combo of Universal&#39;s musical <a href="https://www.hollywoodreporter.com/t/wicked/">Wicked</a> and Paramount&#39;s <a href="https://www.hollywoodreporter.com/t/gladiator-ii/">Gladiator II</a>.
Fueled largely by females, Wicked grossed a huge $11 million in Thursday previews from 3,3000 cinemas for a total preview tally of $19.2 million when factoring in special advance screenings held over the past week. On Monday, Amazon Prime screenings generated $2.5 million at 750 theaters, while advance screenings on Wednesday generated another $5.7 million from 2,000 theaters.
Filmmaker Jon M. Chu&#39;s adaptation of the popular Broadway musical boasts a high-profile cast led by <a href="https://www.hollywoodreporter.com/t/ariana-grande/">Ariana Grande</a> and Cynthia Erivo, and should score one of the top opening of all time for a musical, and particularly a live-action musical (think anywhere from $85 million to $150 million). That&#39;s good news for the genre, which has a decidedly mixed record. It&#39;s also good news for Universal, which took a major gamble in making two movies. Wicked II hits theaters a year from now.
The $150 film was originally set to open Nov. 27, the day before Thanksgiving, but moved up to build word of mouth heading into Thanksgiving week. The new date also allows gives it some breathing room from Disney&#39;s <a href="https://www.hollywoodreporter.com/t/moana-2/">Moana 2</a>, which sails into theaters on the 27th. Moana 2 is likewise looking like a monster and is expected to lead the biggest five-day holiday weekend of all time (Wednesday through Sunday).
Social media has been abuzz with speculation that Gladiator II and Wicked will replicate the Barbenheimer effect this weekend and be the perfect pairing in terms of attracting males and females to the multiplex. Wicked presently boasts an 89 percent fresh ratings critics score on Rotten Tomatoes and Gladiator, 72 percent.
Originally based on the best-selling novel by Gregory Maguire &mdash; Wicked tells the untold story of the witches of Oz, with Erivo as Elphaba and Grande as Glinda. Winnie Holzman, the stage production&#39;s book writer, wrote the screenplay for Chu&#39;s movie with Dana Fox. Academy Award-winning composer and lyricist Stephen Schwartz adapted the musical for the screen.
Directed by Ridley Scott, the $250 million Gladiator sequel opens 24 years after the first film and is looks to open to hearty $65 million or thereabouts. The follow-up stars Paul Mescal, <a href="https://www.hollywoodreporter.com/t/denzel-washington/">Denzel Washington</a>, Connie Nielsen and Fred Hechinger, among others.
&nbsp;
<a href="https://www.hollywoodreporter.com/movies/movie-news/gladiator-2-trailer-paul-mescal-1236009553/">The film </a>sees Mescal playing a grown-up Lucius Verus II, a nephew of Emperor Commodus from the original film, played by Joaquin Phoenix. Lucius returns to Rome after being forced into slavery to battle not as a ruler but as a gladiator out for revenge and power, seeking to return the glory of Rome to its people.

CMCSA

IMAX

PARA

"Box Office: 'Wicked' Earns Huge $19M From Week-Long Previews, 'Gladiator II' Soars to $6.5M on Thursday Alone" - Hollywood Reporter

WIIM

ONDS

Ondas shares are trading higher after the company announced it received a purchase order for the iron drone raider counter-drone system from an Israeli defense company.

INDP

Indaptus Therapeutics shares are trading lower. The company announced a $2.135 million direct offering and private placement.

RBC Capital analyst Deane Dray maintains Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) with a Sector Perform and lowers the price target from $99 to $93.

ATKR

RBC Capital Maintains Sector Perform on Atkore, Lowers Price Target to $93

Scotiabank analyst Tomas Gonzalez downgrades Enel Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENIC#NYSE">ENIC</a>) from Sector Outperform to Sector Perform and maintains the price target from $3.9 to $3.9.

ENIC

Scotiabank Downgrades Enel Chile to Sector Perform, Maintains Price Target to $3.9

Politics

General

HOOD

Robinhood Chief Legal Officer Dan Gallagher Says Not Interested In Being Considered For The U.S. SEC Chair Role

Although Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is up over 190% year-to-date, &#8220;over the last five months the stock has been relatively flat, leaving bulls and bears at an inflection point,&#8221; <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40652895/exclusive-beyond-the-magnificent-seven-direxions-egilinsky-reveals-top-sector-picks">Direxion&#8216;s Ed Egilinsky says</a>.
This pause in growth signals the stock might be priced to perfection. Some active traders are watching for the next move. 
For those who consider the stock&#8217;s price is perfection and forward expectations are not lofty enough to propel it higher, the Direxion Daily NVDA Bear 1X Shares ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDD#NASDAQ">NVDD</a>) offers a way to get profit from any expected correction in the stock. 
However, traders who believe the stock will trend higher in the short term, can look to trade the Direxion Daily NVDA Bull 2X Shares ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDU#NASDAQ">NVDU</a>).
Read Also: <a href="https://www.benzinga.com/news/global/24/11/42129914/jim-cramer-doubles-down-on-nvidia-demand-is-accelerating-as-ai-customers-have-no-choice-but-to-buy-its-chips">Jim Cramer Doubles Down On Nvidia: &#8216;Demand Is Accelerating&#8217; As AI Customers &#8216;Have No Choice&#8217; But To Buy Its Chips</a>
<h2 class="wp-block-heading">Potential R&amp;D Spending Not Baked In</h2>
While Nvidia remains the barometer for the AI space, Egilinsky stresses the importance of continued innovation to retain its competitive edge in AI chips. 
&#8220;This could result in a more sizable commitment to their R&amp;D spending that might not be totally baked into current projections,&#8221; he said.
<h2 class="wp-block-heading">Geopolitical Tensions, Tariffs Could Impact Future Growth</h2>
Beyond its product and performance, Nvidia's future is increasingly shaped by geopolitical risks, particularly the U.S. tariff stance. 
&#8220;Traders will be waiting for a sign to trade the next move in Semis and for short-term traders that can be either a bullish view or bearish sentiment,&#8221; Egilinsky said.
The Donald Trump administration's policies on global trade, especially tariffs, could affect Nvidia's revenue from China and its reliance on Taiwan for chip production.
<h2 class="wp-block-heading">AI Growth Still Promising, But Tariffs Add Uncertainty</h2>
Despite these risks, Nvidia's future looks promising, especially with Blackwell shipments ramping up next quarter. 
One way to gauge Nvidia's AI growth prospects is by looking at its key customers like Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>). 
These tech giants rely heavily on Nvidia's chips to power their cloud platforms, machine learning, and data centers. As these companies expand their AI operations, Nvidia's role in driving this growth could bolster its position in the market, fueling continued demand for its products.
Egilinsky said the excessive demand for Nvidia&#8217;s products might &#8220;send the stock to new all-time highs.&#8221; Still, the company's ability to navigate geopolitical hurdles will be crucial to sustaining this growth.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42121215/nvidia-post-earnings-jitters-can-nvda-stock-regain-its-ai-fueled-momentum">Nvidia&#8217;s Post-Earnings Jitters: Can NVDA Stock Regain Its AI-Fueled Momentum?</a></li>
</ul>

Long Ideas

Trading Ideas

AMZN

MSFT

NVDA

NVDD

NVDU

Nvidia 'Bulls And Bears At An Inflection Point,' Expert Says: Will AI Growth Overcome Global Tariff Risks?

<a href="https://www.ft.com/content/739bed04-fce1-4429-bbfd-64979e6bf395">https://www.ft.com/content/739bed04-fce1-4429-bbfd-64979e6bf395</a>

'Unilever To Slim Down But Not Spin Off Food Business, Says Chief' - Financial Times

RBC Capital analyst Rishi Jaluria maintains Clearwater Analytics Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) with a Outperform and raises the price target from $32 to $36.

CWAN

RBC Capital Maintains Outperform on Clearwater Analytics Hldg, Raises Price Target to $36

Nano Labs shares are trading higher after the company announced it unveiled a second-generation of v series crypto mining products with 5x the power efficiency.

QMCO

Quantum Shares Halted On Circuit Breaker To The Downside, Stock Now Up 52.2%

Nutanix's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NYSE">NTNX</a>) short percent of float has fallen 11.79% since its last report. The company recently reported that it has 4.65 million shares sold short, which is 2.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Nutanix Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732290320_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nutanix has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Nutanix's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Nutanix's peer group average for short interest as a percentage of float is 3.38%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

NTNX

(NTNX) - Analyzing Nutanix's Short Interest

LIFW

MSP Recovery shares are trading higher after the company announced it secured a $2 million pharmaceutical settlement.

CSW Industrials's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSWI#NYSE">CSWI</a>) short percent of float has fallen 20.0% since its last report. The company recently reported that it has 397 thousand shares sold short, which is 2.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CSW Industrials Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732290315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CSW Industrials has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing CSW Industrials's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CSW Industrials's peer group average for short interest as a percentage of float is 3.71%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CSWI

(CSWI) - Analyzing CSW Industrials's Short Interest

New York&#8217;s storied real estate dynasties are breaking a rule passed down through generations – never sell your buildings. As the <a href="https://www.benzinga.com/real-estate/24/10/41357339/experts-warn-that-distress-in-u-s-offices-may-lead-to-a-surging-supply-of-one-billion-square-feet-of">office market crumbles under the weight of remote work</a>, New York families are forced to part with properties they&#8217;ve held for decades.
William Rudin, whose family helped shape Manhattan&#8217;s skyline, recently sold control of two financial district towers his family developed in the 1960s. "The world has changed," Rudin, the co-executive chairman of his family's firm, told the Wall Street Journal. "We have to take a cold hard look at our business to make sure there's a foundation for the next generation."
Don't Miss:
<ul>
<li>Invest in $20+ trillion home equity market today across cities like Austin, Miami, and Los Angeles through a <a href="https://www.benzinga.com/money/nada-cityfunds">unique 5-year term fund targeting a 14-20% IRR with minimums as low as $2,500</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
The sales mark a shift for families that have weathered world wars, financial crashes and even a pandemic without letting go of their core assets. According to real estate investment firm Eastdil Secured, New York&#8217;s real estate families have sold about 10 office buildings in the past two years – double the number sold in the previous decade.
"Instead of 50 different aunts and uncles getting distributions, they're getting capital calls," Gary Phillips, an Eastdil managing director, told the WSJ, highlighting the financial strain on extended family businesses.
With a 100-year legacy in Manhattan real estate, the Kaufman family is also reluctantly selling. "We and the other families did not sell," Jonathan Iger, CEO of Sage Realty, the Kaufman family's management firm, said to the WSJ. "You see yourself through the dips and you come out – not just fine, but more than fine."
Trending: Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a>
Some families are fighting to hold on. The Gurals recently invested fresh capital into their 60-year-old DuMont Building on Madison Avenue. "It's called a capital call, which is the most dreaded term in our industry," said Jeffrey Gural, chairman of GFP Real Estate. Despite the pain, Gural remains convinced holding is the right choice. "I have yet to sell a building where I didn't regret selling," he said.
For the Rudins, even a $100 million renovation at 80 Pine Street couldn't save it from the chopping block. "Even if we spent money to fix up the building, the ceilings are too low, there are a lot of columns, the floors are too big," Rudin explained. "It became clear to us we needed to stop putting capital back into the building."
The sales represent more than just business decisions – they're the end of an era for families who built New York's commercial landscape. "When I go by 80 Pine Street, I remember the good times and bad times," Rudin reflected. "But you've got to move on."
The shift might signal a broader transformation in urban real estate, as aging office towers face obsolescence in a <a href="https://www.benzinga.com/markets/24/08/40436855/hopes-for-nyc-office-market-rebound-dented-by-sale-of-midtown-skyscraper-at-97-discount-but-theres-a">post-pandemic world demanding modern amenities and flexible workspaces</a>.
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Real Estate

'I Have Yet to Sell A Building Where I Didn't Regret Selling ': Families Forced To Sell NYC Icons

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics has successfully enrolled 100 patients in its Phase II ARCHER trial, t...

Cardiol Therapeutics' Landmark Enrollment for Heart Drug Trial

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc., a clinical-stage company specializing in heart disease treatment...

Cardiol Therapeutics Announces Public Share Offering

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics, a clinical-stage life sciences company, has announced the pricing of ...

Cardiol Therapeutics Sets Common Share Offering Price

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics, a clinical-stage company specializing in heart disease treatments, ha...

Cardiol Therapeutics Secures $13.5M in Public Offering

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics has successfully completed a public offering, raising $15.525 million ...

Cardiol Therapeutics Raises $15.5 Million in Offering

Cardiol Therapeutics (CRDL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Edward Nash...

Cardiol Therapeutics' Strategic Advancements Boost Market Potential and Revenue Projections

Roth MKM analyst Jason Wittes maintained a Buy rating on Cardiol Therapeutics (CRDL – Research Report) today and set a price target of $10.00. The ...

Cardiol Therapeutics (CRDL) Gets a Buy from Roth MKM

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics reports a significant net loss of $28.5 million for the nine months en...

Cardiol Therapeutics Faces Rising Losses and Falling Assets

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics has announced promising results from its Phase II MAvERIC-Pilot study,...

Cardiol Therapeutics Reports Promising Phase II Results

Edward Nash Reaffirms Buy Rating for Cardiol Therapeutics: Positive Phase II Data and Strategic Future Trials Boost Market Potential

CRDL

Press Releases

Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Cover – see more stocks inside…

"Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge"

Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN

"7 Stocks Experiencing Significant Short Covering: RDDT, LYFT, BROS, and More Small-Cap Opportunities Inside"

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

"Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors"

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Comments

Cardiol Therapeutics

Interés en corto

Cardiol Therapeutics (NASDAQ:CRDL) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL